Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
121. |
ECCT/14/08/05 | Brief Bactericidal Activity of Anti TB drugs Brief Bactericidal Activity of Anti-Tuberculosis Drugs |
Principal Investigator(s) 1. Videlis Nzioka Nduba Site(s) in Kenya KEMRI-CGHR |
18-11-2014 |
View |
122. |
ECCT/20/11/04 | FAST Study Assessments of the EFficacy, the onset-of-Action and the Safety of Tot'héma® in adults with moderate iron deficiency anaemia |
Principal Investigator(s) 1. Naftali Wasindi Busakhala 2. Otieno Odhiambo Fredrick Site(s) in Kenya 1. MOI University Teaching and Referral Hospita (Nandi county) 2. UNIM Research and Training Centre (Kisumu county) 3. Kenyatta National Hospital (Nairobi City county) |
27-02-2021 |
View |
123. |
ECCT/13/03/01 | Assessing the acceptability of a progesterone vaginal ring (PVR) as a new contraceptive option in sub-Saharan Africa |
Principal Investigator(s) 1. Obare Francis Site(s) in Kenya 1. Ngoliba Health Centre (Kiambu county) 2. Kirwara Sub-district Hospital (Kiambu county) 3. Igegania Sub-district Hospital (Kiambu county) 4. Makadara Health Centre (Nairobi City county) 5. Thika Level 5 (Kiambu county) 6. Ruiru Sub-district Hospital (Kiambu county) |
13-02-2013 |
View |
124. |
ECCT/23/12/05 | Annovera Acceptability Study Assessing acceptability of Annovera contraceptive vaginal ring use (compared to other contraceptive method use) among women seeking family planning services |
Principal Investigator(s) 1. Elizabeth Anne Bukusi Site(s) in Kenya KEMRI-CMR-RCTP Nairobi |
17-03-2024 |
View |
125. |
ECCT/17/07/01 | ABCD Antibiotics for Children with Severe Diarrhea Trial |
Principal Investigator(s) 1. Judd Walson Site(s) in Kenya 1. Rongo Sub-County Hospital (Migori county) 2. Ndhiwa Sub-County Hospital (Homa Bay county) 3. Rachuonyo Sub-County Hospital (Homa Bay county) 4. Isebania Sub-County Hospital (Migori county) 5. Awendo Sub-County Hospital (Migori county) 6. Mbita Sub-County Hospital (Homa Bay county) |
01-12-2017 |
View |
126. |
ECCT/16/12/01 | The Partners Scale-Up Project Animplementation project to scale-up delivery of antiretroviral-based HIV-1 prevention amongKenyan HIV-1 serodiscordant couples. |
Principal Investigator(s) 1. Prof. Elizabeth Ann Bukusi Site(s) in Kenya 1. KISUMU SITE (Kisumu county) 2. Thika Site (Kiambu county) |
13-02-2017 |
View |
127. |
ECCT/19/02/01 | DANCE Study An Open-Label, Single Arm Study to Evaluate the Week 48 Efficacy and Safety of a Two-Drug Regimen of Dolutegravir/Lamivudine (DTG/3TC) as a Fixed Dose Combination (FDC), in Antiretroviral Therapy (ART)-Naive HIV-1-Infected Adolescents, ≥12 To <18 Years of Age who Weigh at Least 40 Kg. |
Principal Investigator(s) 1. Fredrick Odhiambo Otieno 2. Isaac Tsikhutsu Site(s) in Kenya 1. Nyanza Reproductive Health Society (Kisumu county) 2. Kenya Medical Research Institute (Kisumu county) 3. Kenya Medical Research Institute, Walter Reed Project (Kericho county) |
14-08-2019 |
View |
128. |
ECCT/13/03/02 | An open-label, pilot demonstration and evaluation project of antiretroviral-based HIV-1 prevention among high-risk HIV-1 serodiscordant African couples An open-label, pilot demonstration and evaluation project of antiretroviral-based HIV-1 prevention among high-risk HIV-1 serodiscordant African couples The Partners PrEP Study Demonstration Project |
Principal Investigator(s) 1. DR.ELIZABETH ANNE BUKUSI ELIZABETH ANNE BUKUSI Site(s) in Kenya 1. THIKA (Nairobi City county) |
10-07-2012 |
View |
129. |
ECCT/12/08/01 | Partners Demonstration Project An open-label, pilot demonstration and evaluation project of antiretrovira-based HIV-1 prevention among high-risk HIV-1 serodiscordant African couples. |
Principal Investigator(s) 1. Dr. Nelly Rwamba Mugo Site(s) in Kenya 1. Partners in Prevention, Thika Site (Kiambu county) 2. Partners in Prevention, Kisumu Site (Kisumu county) |
01-10-2012 |
View |
130. |
ECCT/19/04/03 | Phase III pediatric study with the L-PZQ ODTs An Open-label, Phase 3 efficacy and safety study of L-praziquantel orodispersible tablets (L-PZQ ODT) in Schistosoma-infected children 3 months to 6 years of age, including a 2:1 randomized, controlled cohort of Schistosoma mansoni-infected children 4 to 6 years of age treated with L-PZQ ODT or commercial PZQ (Biltricide®) |
Principal Investigator(s) 1. Maurice Reuben Odiere Site(s) in Kenya KEMRI-Centre for Global Health Research (CGHR) |
18-06-2019 |
View |